AKRO Akero Therapeutics Inc.

24.5
+1.19  (+5%)
Previous Close 23.31
Open 23.4
Price To Book 4.88
Market Cap 699,686,999
Shares 28,558,653
Volume 167,795
Short Ratio
Av. Daily Volume 168,542
Stock charts supplied by TradingView

NewsSee all news

  1. Akero Therapeutics Expands Phase 2a Trial in NASH to Include Cohort of Cirrhotic Patients

    SAN FRANCISCO, Jan. 13, 2020 /PRNewswire/ -- Akero Therapeutics, Inc. (NASDAQ:AKRO), a clinical-stage biotechnology company developing transformational treatments for patients with non-alcoholic steatohepatitis (NASH)

  2. Akero Therapeutics To Present At The 2020 J.P. Morgan Healthcare Conference

    SAN FRANCISCO, Jan. 8, 2020 /PRNewswire/ -- Akero Therapeutics, Inc. (NASDAQ:AKRO), a clinical-stage biotechnology company developing transformational treatments for patients with non-alcoholic steatohepatitis (NASH) and

  3. Akero Therapeutics Completes Enrollment in Phase 2a Study in NASH

    SAN FRANCISCO, Dec. 16, 2019 /PRNewswire/ -- Akero Therapeutics, Inc. (NASDAQ:AKRO), a clinical-stage biotechnology company developing transformational treatments for patients with non-alcoholic steatohepatitis (NASH)

  4. Akero Therapeutics to Present at the Jefferies 2019 London Healthcare Conference

    SAN FRANCISCO, Nov. 13, 2019 /PRNewswire/ -- Akero Therapeutics, Inc. (NASDAQ:AKRO), a clinical-stage biotechnology company developing transformational treatments for patients with non-alcoholic steatohepatitis (NASH)

  5. Akero Therapeutics Reports Recent Highlights and Third Quarter 2019 Financial Results

    SAN FRANCISCO, Nov. 12, 2019 /PRNewswire/ -- Akero Therapeutics, Inc. (NASDAQ:AKRO), a clinical-stage biotechnology company developing transformational treatments for patients with non-alcoholic steatohepatitis (NASH)

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2a data due 1Q 2020 (MRI‐PDFF).
AKR-001
Nonalcoholic steatohepatitis (NASH)

Latest News

  1. Akero Therapeutics Expands Phase 2a Trial in NASH to Include Cohort of Cirrhotic Patients

    SAN FRANCISCO, Jan. 13, 2020 /PRNewswire/ -- Akero Therapeutics, Inc. (NASDAQ:AKRO), a clinical-stage biotechnology company developing transformational treatments for patients with non-alcoholic steatohepatitis (NASH)

  2. Akero Therapeutics To Present At The 2020 J.P. Morgan Healthcare Conference

    SAN FRANCISCO, Jan. 8, 2020 /PRNewswire/ -- Akero Therapeutics, Inc. (NASDAQ:AKRO), a clinical-stage biotechnology company developing transformational treatments for patients with non-alcoholic steatohepatitis (NASH) and

  3. Akero Therapeutics Completes Enrollment in Phase 2a Study in NASH

    SAN FRANCISCO, Dec. 16, 2019 /PRNewswire/ -- Akero Therapeutics, Inc. (NASDAQ:AKRO), a clinical-stage biotechnology company developing transformational treatments for patients with non-alcoholic steatohepatitis (NASH)

  4. Akero Therapeutics to Present at the Jefferies 2019 London Healthcare Conference

    SAN FRANCISCO, Nov. 13, 2019 /PRNewswire/ -- Akero Therapeutics, Inc. (NASDAQ:AKRO), a clinical-stage biotechnology company developing transformational treatments for patients with non-alcoholic steatohepatitis (NASH)

  5. Akero Therapeutics Reports Recent Highlights and Third Quarter 2019 Financial Results

    SAN FRANCISCO, Nov. 12, 2019 /PRNewswire/ -- Akero Therapeutics, Inc. (NASDAQ:AKRO), a clinical-stage biotechnology company developing transformational treatments for patients with non-alcoholic steatohepatitis (NASH)

  6. Arbutus Reports Third Quarter 2019 Financial Results and Provides Corporate Update

    WARMINSTER, Pa., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (NASDAQ:ABUS), a Hepatitis B Virus (HBV) therapeutic solutions company, today reports its third quarter 2019 financial results and

  7. InSphero Wins Sino-European Innovation Award for Breakthrough NASH Discovery and Safety Testing Platform

    SCHLIEREN, Switzerland, Nov. 4, 2019 /PRNewswire/ -- InSphero AG today announced the company received an award at the 2019 Sino-European Innovation Week in Healthcare Technology (SEIWHT) meeting held in Nanjing, China.